The Blood-Testis Barrier and Its Implications for Male Contraception

Cheng CY, Mruk DD

Published January 2012 Pharmacological Reviews, 64(1), 16-64
DOI 10.1124/pr.110.002790 PMC PMC3250082

RRM Academy Synopsis

How the Blood-Testis Barrier Blocks Male Contraceptive Drugs

This is a 2012 lab review of rat studies. The review examines the blood-testis barrier, a tight seal that protects growing sperm cells. Less than 1% of one test drug reached the testis when rats took it by mouth. The finding shows how strongly the barrier blocks new male birth control drugs that skip hormones.

Key Findings

  • In rats given either a low or high dose of the experimental drug adjudin, all sperm-forming cells except stem cells disappeared from the testis within about 2 weeks.
  • At the lower dose, normal sperm production started returning around 20 weeks, and more than 70% of tubules were producing sperm normally again by 30 weeks; the higher dose failed to recover.
  • Less than 1% of adjudin given orally to rats reached the testis, leaving little room between a dose strong enough to work and one that could cause harm.
  • Reducing one drug transport protein by about 70% cut the drug's delivery into the testis's inner compartment by about 30%; blocking four such proteins together cut delivery by more than 70%.
  • Roughly 60% of the about 800 known drug transporter proteins in mammals are built into cell membranes, and many sit in the cells that form the blood-testis barrier.

Interpretation

This review brings together years of rat and cell research on how the blood-testis barrier forms and how drugs cross it. The barrier is a real, well-studied block to getting drugs into the testis, whether for birth control or for treating other problems there. Drug transport proteins in the barrier cells control much of that traffic, and targeting them changes how much drug gets through. The findings support larger studies of drug-delivery methods that can carry an effective, non-hormonal dose into the testis safely.

RRM Context

RRM Academy treats this as background science. The review is not care advice. The review also shows how things like cadmium and bisphenol A can hurt the blood-testis barrier and lower sperm counts. That is one way male infertility can start. The drugs studied here are not an RRM method. They work by shutting down sperm production on purpose. RRM instead looks for the cause of infertility in both partners and treats it.

Abstract

The blood-testis barrier (BTB) is one of the tightest blood-tissue barriers in the mammalian body. It divides the seminiferous epithelium into the basal and the apical (adluminal) compartments. Meiosis I and II, spermiogenesis, and spermiation all take place in a specialized microenvironment behind the BTB in the apical compartment, but spermatogonial renewal and differentiation and cell cycle progression up to the preleptotene spermatocyte stage take place outside of the BTB in the basal compartment of the epithelium. However, the BTB is not a static ultrastructure. Instead, it undergoes extensive restructuring during the seminiferous epithelial cycle of spermatogenesis at stage VIII to allow the transit of preleptotene spermatocytes at the BTB. Yet the immunological barrier conferred by the BTB cannot be compromised, even transiently, during the epithelial cycle to avoid the production of antibodies against meiotic and postmeiotic germ cells. Studies have demonstrated that some unlikely partners, namely adhesion protein complexes (e.g., occludin-ZO-1, N-cadherin-β-catenin, claudin-5-ZO-1), steroids (e.g., testosterone, estradiol-17β), nonreceptor protein kinases (e.g., focal adhesion kinase, c-Src, c-Yes), polarity proteins (e.g., PAR6, Cdc42, 14-3-3), endocytic vesicle proteins (e.g., clathrin, caveolin, dynamin 2), and actin regulatory proteins (e.g., Eps8, Arp2/3 complex), are working together, apparently under the overall influence of cytokines (e.g., transforming growth factor-β3, tumor necrosis factor-α, interleukin-1α). In short, a "new" BTB is created behind spermatocytes in transit while the "old" BTB above transiting cells undergoes timely degeneration, so that the immunological barrier can be maintained while spermatocytes are traversing the BTB. We also discuss recent findings regarding the molecular mechanisms by which environmental toxicants (e.g., cadmium, bisphenol A) induce testicular injury via their initial actions at the BTB to elicit subsequent damage to germ-cell adhesion, thereby leading to germ-cell loss, reduced sperm count, and male infertility or subfertility. Moreover, we also critically evaluate findings in the field regarding studies on drug transporters in the testis and discuss how these influx and efflux pumps regulate the entry of potential nonhormonal male contraceptives to the apical compartment to exert their effects. Collectively, these findings illustrate multiple potential targets are present at the BTB for innovative contraceptive development and for better delivery of drugs to alleviate toxicant-induced reproductive dysfunction in men.

Related research

C. Yan Cheng, Dolores D. Mruk
D Mruk
DOI 10.1124/pr.110.002790 10.1124/pr.110.002790 Cheng et al. 2012, Cheng 2012